Evidence map›Paper›PMID 1357974›Full record

ArticleThe American journal of pathology1992

Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.

C L Collins, N G Ordonez, R Schaefer, C D Cook, S S Xie, J Granger, P L Hsu, L Fink, S M Hsu

Open access · greenAbstract read
In one paragraph

Article in The American journal of pathology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 131 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

C L CollinsDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock.
N G Ordonez
R Schaefer
C D Cook
S S Xie
J Granger
P L Hsu
L Fink
S M Hsu
University of Arkansas for Medical Sciences · US

Funding

STUDY OF NOVEL CYTOKINE DERIVED FROM HODGKIN'S CELL LINER01CA047462 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HSU, SU-MING · 1988 to 1990
–
NCI NIH HHS CA47462
6 · The paper itself

Abstract

Thrombomodulin (TM) is a glycoprotein of molecular weight 75,000 kd that is normally present in restricted numbers of cells, including endothelial and mesothelial cells. In this study, the authors tested the possibility of using anti-TM to facilitate the diagnosis of mesothelioma. All of the 31 mesotheliomas and the two mesothelioma cell lines (MS-1 and MS-2) tested were stained positively with anti-TM. The specificity of anti-TM staining in mesothelioma cells was further confirmed by in situ hybridization of MS-1 cells with a TM-specific probe. The expression of TM in MS-1 cells was increased markedly when these cells were induced by 12-0-tetradecanyl phorbol 13-acetate (TPA) to differentiate. The expression of TM in mesothelioma cells, however, did not correlate with any particular phase of the cell cycle. In an attempt to differentiate pleural mesothelioma from pulmonary adenocarcinoma, the authors compared the expression of TM, carcinoembryonic antigen (CEA), and Leu M1 in these two types of tumors. Only four of 48 (8%) pulmonary adenocarcinomas were stained positively by antibodies to TM. Therefore, immunohistochemical staining with antibodies to TM yielded 100% sensitivity and 92% specificity for diagnosis of mesothelioma. All of the mesotheliomas stained negatively for CEA and Leu M1, except for one, which showed minimal focal positivity for Leu M1. In contrast, 79% and 60% of adenocarcinomas stained positively for CEA and Leu M1, respectively. These findings suggest that immunocytochemical staining with anti-TM should be added to the battery of tests to increase the diagnostic sensitivity and specificity for differentiating mesothelioma from pulmonary adenocarcinoma.

Indexed as

AdenocarcinomaAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorCarcinoembryonic AntigenCell CycleDiagnosis, DifferentialHumansIn Situ HybridizationLewis X AntigenLungLung NeoplasmsMesotheliomaReceptors, Cell SurfaceReceptors, ThrombinTetradecanoylphorbol AcetateAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorCarcinoembryonic AntigenLewis X AntigenReceptors, Cell SurfaceReceptors, ThrombinTetradecanoylphorbol Acetate

Identifiers

PMID1357974
PMCPMC1886631
OpenAlexW5891818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.